Fluoxetine treatment and testosterone levels

Annals of Clinical Psychiatry

Volumn 18, Issue 1, 2006, Pages 19-22

  Bell, Stewart ^a   Shipman, Mark ^b   Bystritsky, Alexander ^c   Haifley, Tim ^a  

^a University of California ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressive agents; Apathy; Fluoxetine; Serotonin reuptake inhibitors; Testosterone

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; TESTOSTERONE; SEROTONIN UPTAKE INHIBITOR;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; APATHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DRUG EFFECT; DRUG RESPONSE; DRUG USE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUAL DYSFUNCTION; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; AROUSAL; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG SURVEILLANCE PROGRAM; MOTIVATION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AROUSAL; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; MALE; MOTIVATION; PILOT PROJECTS; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; TESTOSTERONE;

EID: 33646839490     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230500464612     Document Type: Article

References (12)

1. Bell S, Shipman M: Reduced testosterone level in a venlafaxine treated patient. Ann Clin Psychiatry 2000; 12(3):171-173
2. Aguirre B: Fluoxetine and compulsive sexual behavior [letter]. J Am Acad Child Adolesc Psychiatry 1999; 38(8):943
3. Murphy S, Khaw Kt, Cassidy A, Compston JE: Sex hormones and bone mineral density in elderly men. J Bone Miner Res 1993; 20(2):133-140
4. Jackson JA, Riggs MW, Spiekerman AM: Testosterone deficiency as a risk factor for hip fractures in men: A case-control study. Am J Med Sci 1992; 304(1):4-8
5. Taylor G, Bardgett M, Csernansky J, Early T, Haller J, Scherrer J, Womack S: Male reproductive systems under chronic fluoxetine or trimipramine treatment. Physiol Behav 1996; 59(3):479-485
6. Bonilla-Jaime H, Retana-Marquez S, Vazquez-Palacios G, Velazquez-Moctezuma J: Plasma levels of corticosterone and testosterone after sexual activity in male rats treated neonatally will clomipramine. Behav Pharmacol 2003; 14(4):357-362
7. Von Bardeleben U, Steiger A, Gerken A, Holsboer F: Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal controls. Int Clin Psychopharmacol 1989; 4(Suppl 1): 1-5
8. Cohen PG, Holbrook JM: Effects of fenfluramine on ejaculatory function, luteinizing hormone and testosterone levels in men with hypogonadotropic hypogonadism and premature ejaculation. Int Clin Psychopharmacol 1999; 14(2):91-94
9. Steiger A, Gerken A, Benkert O, Holsboer F: Differential effects of the enantiomers R(-) and S(+) oxaprotiline on major endogenous depression, the sleep EEG and neuroendocrine secretion: Studies on depressed patients and normal controls. Eur Neuropsychopharmacol 1993; 3:117-126
10. Maier U, Koinig G: Andrological findings in young patients under long-term antidepressive therapy with clomipramine. Psychopharmacology (Berl) 1994; 116(3):357-359
11. Sonntag A, Rothe B, Guldner J, Yassouridis A, Holsboer F, Steiger A: Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 1996; 4(1):1-13
12. Groom GV: The measurement of human gonadotrophins by radioimmunoassay. J Reprod Fertil 1977; 51:273